Smart Health Wearables Landmark: UTime Subsidiary Secures 50,000-Unit Mega Order, Opening New Chapter for UTime’s Expansion into the North American Market

UTime (Nasdaq: WTO) announced that its Hong Kong subsidiary signed a commercial sales agreement worth nearly $10 million with Denver-based Tumu Vertex LLC for an initial purchase order of 50,000 smart health devices.

Rhea-AI Summary

UTime (Nasdaq: WTO) announced that its Hong Kong subsidiary signed a commercial sales agreement worth nearly $10 million with Denver-based Tumu Vertex LLC for an initial purchase order of 50,000 smart health devices.

The order is described as 25,000 units of the UT-168 BT Blood Pressure Watch and 25,000 units of the UR08 ECG Smart Ring, with FOB Hong Kong delivery, phased payments, joint quality-control procedures, and first deliveries starting in Q1 2026. UTime highlights FDA-certified medical-grade monitoring integrated into everyday wearables and positions the deal as a strategic entry into the North American medical-grade wearable market.

Positive

• Signed nearly $10 million sales agreement for 50,000 devices
• Order split: 25,000 UT-168 watches and 25,000 UR08 rings
• First deliveries scheduled in Q1 2026
• Agreement uses FOB Hong Kong, phased payments, joint QC

Negative

• Customer concentration: single 50,000-unit initial order
• Revenue and shipment timing tied to phased payments and delivery

Argus Dec 31 session

+61.09% close to close Open Argus

Details

News Market Reaction – WTO

On Dec 31, the day this news came out, WTO closed 61.09% above the previous close.

Data tracked by StockTitan Argus for the Dec 31 session.

Key Figures

Order value: nearly $10 million USD Total units ordered: 50,000 units UT-168 BT Blood Pressure Watch: 25,000 units +4 more

Order value

nearly $10 million USD

Smart health device procurement agreement with Tumu Vertex LLC

Total units ordered

50,000 units

Initial purchase order under Sales Agreement

UT-168 BT Blood Pressure Watch

25,000 units

Portion of 50,000-unit order

UR08 ECG Smart Ring

25,000 units

Portion of 50,000-unit order

UT-368 4G Blood Pressure Watch

25,000 units

Additional product line in order

UR01 Smart Ring

25,000 units

Additional product line in order

First delivery timing

Q1 2026

Initial batch of products to begin delivery

Historical Context

5 past events · Latest: Nov 12

5 events

1. Nov 12

   Reverse stock split

   24h Move

   -5.3%

   1-for-100 reverse split to support Nasdaq minimum bid compliance.

2. Nov 05

   Market expansion

   24h Move

   -0.2%

   Plans to expand smart wearable distribution through global channels and partners.

3. Nov 03

   AI R&D update

   24h Move

   +14.5%

   Research into AI models for health data and hypertension risk assessment.

4. Oct 30

   Product launch

   24h Move

   -10.7%

   Launch of smart ring focused on sleep and continuous health monitoring.

5. Oct 28

   Product launch

   24h Move

   +2.4%

   Launch of smartwatch with integrated blood pressure monitoring and NMPA registration.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

ECG, FDA-certified, medical-grade, FOB

4 terms

ECG medical

"25,000 units of the UR08 ECG Smart Ring."

An ECG (electrocardiogram) records the heart’s electrical activity through small sensors on the skin and produces a waveform that shows heart rate, rhythm and signs of stress or damage—think of it as a seismograph for the heart’s electrical signals. Investors care because ECGs are central to diagnosing and monitoring cardiac safety in clinical trials, required for regulatory approval of many drugs and devices, and drive demand for related medical equipment and services.

FDA-certified regulatory

"combines FDA-certified medical-grade monitoring technology with everyday wearable"

A term often used to signal that a product, facility or process has met some requirement of the U.S. Food and Drug Administration (FDA), but it is not a single, formal FDA designation. Think of it like a product label that suggests official approval or acceptance—like a “quality badge” on a package—yet the exact meaning can range from full FDA approval to simple registration or listing; investors should verify the specific type and scope of FDA action because that affects regulatory risk and commercial prospects.

medical-grade medical

"FDA-certified medical-grade monitoring technology with everyday wearable scenarios"

Medical-grade describes products, materials or devices manufactured and tested to meet standards required for clinical or hospital use, including higher purity, sterilization and quality controls than consumer versions. Think of it as 'built to hospital standards' the way safety-certified equipment differs from home gadgets. For investors, medical-grade status matters because it influences regulatory approval, pricing, market access, liability and the likelihood of stable contracts and higher profit margins.

FOB technical

"follows internationally recognized trade frameworks, covering FOB Hong Kong delivery"

FOB (Free On Board) is a shipping contract term that specifies the exact point when ownership, shipping costs, and liability for goods shift from the seller to the buyer. Think of it like handing over the keys when a car crosses a line: once the goods pass that point (often the seller’s dock or the ship’s rail), the buyer is responsible for transport, insurance, and any loss. For investors, FOB affects cash flow, inventory timing, and which party bears shipping risk and expense, all of which influence profit margins and balance-sheet reporting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SHENZHEN, China, Dec. 31, 2025 (GLOBE NEWSWIRE) -- UTime Limited (Nasdaq: WTO), a global technology company engaged in the design and development of mobile devices today announced a major commercial breakthrough. UTime’s Hong Kong subsidiary, UTime Technology (HK) Company Limited, has officially signed a smart health device procurement agreement worth nearly $10 million USD with Tumu Vertex LLC, a Denver-based entity, marking a crucial step in UTime's strategic deployment in the North American medical-grade smart wearable market.

Under the signed Sales Agreement, Tumu Vertex LLC has placed an initial purchase order for 50,000 premium smart health devices from UTime, comprising:

• 25,000 units of the UT-168 BT Blood Pressure Watch and 25,000 units of the UR08 ECG Smart Ring.
  
  
• 25,000 units of the UT-368 4G Blood Pressure Watch and 25,000 units of the UR01 Smart Ring
  
  

We believe this collaboration represents not only a breakthrough in volume but also brings us to a new level in technological integration. UTime's solution perfectly combines FDA-certified medical-grade monitoring technology with everyday wearable scenarios, representing the latest development trend in the smart health industry. The agreement follows internationally recognized trade frameworks, covering FOB Hong Kong delivery, phased payments, and standardized quality assurance systems.

"This cooperation represents a significant strategic breakthrough for us in the North American market," stated UTime's CEO during the signing ceremony. "As our important partner in Colorado, Tumu Vertex's order for 50,000 units demonstrates not only market recognition of our technological capabilities but also opens the door to the North American medical-grade wearable market. We aim to use this opportunity to accelerate the development and implementation of next-generation health monitoring technologies as part of our product portfolio."

The founder and Chief Executive Officer of Tumu Vertex LLC, Monil Hossain, commented: "UTime's technological innovation and product quality have deeply impressed us. These devices will be used for our smart health service platform in the United States, providing users with 24/7 health monitoring solutions. We look forward to establishing long-term strategic cooperation with UTime."

According to the agreement, the first batch of products will begin delivery in the first quarter of 2026, with all products undergoing joint quality control procedures established by both parties.

As populations worldwide are living longer and obtaining greater health awareness, UTime believes the smart health device market is primed for explosive growth. We believe this major purchase order will help consolidate UTime’s position in the consumer electronics field while laying a solid foundation for the company's strategic growth in the medical technology sector.

About UTime Limited

Trading under the NASDAQ ticker WTO, UTime Limited is engaged in the design, development, production, sales and brand operation of mobile devices and smart wearable devices and other technology in China and globally. The company aims to provide cost-effective products while serving a broad customer base.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. For additional risk factors, please review UTime Limited’s Annual Report on Form 20-F and other SEC filings. Forward-looking statements are made only as of the date of this release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required under applicable law.

Contact:
qhengcong@utimemobile.com

UTime Limited
7th Floor, Building 5A
Shenzhen Software Industry Base, Nanshan District
Shenzhen, People’s Republic of China 518061
Tel: (86) 755 865122

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did UTime (WTO) announce on December 31, 2025?

UTime announced a nearly $10 million sales agreement with Tumu Vertex for 50,000 smart health devices.

How are the 50,000 devices for WTO ordered by Tumu Vertex allocated?

The order is described as 25,000 UT-168 BT Blood Pressure Watches and 25,000 UR08 ECG Smart Rings.

When will UTime begin shipping the WTO devices to Tumu Vertex?

The first batch is scheduled for delivery beginning in Q1 2026.

What delivery and payment terms did WTO report for the Tumu Vertex order?

The agreement covers FOB Hong Kong delivery and phased payments with joint quality control procedures.

Does UTime say the devices are medical-grade for WTO investors?

UTime states the devices combine FDA-certified medical-grade monitoring with everyday wearable designs.

What does the Tumu Vertex order mean for UTime's (WTO) North American strategy?

UTime describes the order as a strategic breakthrough to accelerate its entry into the North American medical-grade wearable market.